Marcia Barbosa Aguila

Marcia Barbosa Aguila

Auto-generated profile, based on publicly available information

Marcia Barbosa Aguila

Laboratory of Morphometry, Metabolism, and Cardiovascular disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Clinical Biochemistry and Nutrition
Verified
Journal Article
Open access
JFJulio C. Fraulob
Julio C. Fraulob
RORebeca Ogg-Diamantino
Rebeca Ogg-Diamantino
Caroline Fernandes-SantosCaroline Fernandes-Santos
Caroline Fernandes-Santos
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
Diet-induced obesity in C57BL/6 mice triggers common features of human metabolic syndrome (MetS). The purpose is to assess the suitability of a diet-induced obesity model for investigating non-alcoholic fatty pancreatic disease (NAFPD), fatty liver and insulin resistance. Adult C57BL/6 mice were fed either high-fat chow (HFC, 60% fat) or standard chow (SC, 10% fat) during a 16-week period. We evaluated in both groups: hepatopancreatic injuries, pancreatic islets size, alpha and beta-cell immunodensities, intraperitoneal insulin tolerance test (IPITT) and oral glucose tolerance test (OGTT). The HFC mice displayed greater mass gain (p<0.0001) and total visceral fat pads (p<0.001). OGTT showed impairment of glucose clearance in HFC mice (p<0.0001). IPITT revealed insulin resistance in HFC mice (p<0.0001). The HFC mice showed larger pancreatic islet size and significantly greater alpha and beta-cell immunodensities than SC mice. Pancreas and liver from HFC were heavier and contained higher fat concentration. In conclusion, C57BL/6 mice fed a high-fat diet develop features of NAFPD. Insulin resistance and ectopic accumulation of hepatic fat are well known to occur in MetS. Additionally, the importance of fat accumulation in the pancreas has been recently highlighted. Therefore, this model could help to elucidate target organ alterations associated with metabolic syndrome.

18 January 2017 in Hormone Molecular Biology and Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TBThereza Cristina Lonzetti Bargut
Thereza Cristina Lonzetti Bargut
VSVanessa Souza-Mello
Vanessa Souza-Mello
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
Beige or brite (brown-in-white) adipocytes are present in white adipose tissue (WAT) and have a white fat-like phenotype that when stimulated acquires a brown fat-like phenotype, leading to increased thermogenesis. This phenomenon is known as browning and is more likely to occur in subcutaneous fat depots. Browning involves the expression of many transcription factors, such as PR domain containing 16 (PRDM16) and peroxisome proliferator-activated receptor (PPAR)-γ, and of uncoupling protein (UCP)-1, which is the hallmark of thermogenesis. Recent papers pointed that browning can occur in the WAT of humans, with beneficial metabolic effects. This fact indicates that these cells can be targeted to treat a range of diseases, with both pharmacological and nutritional activators. Pharmacological approaches to induce browning include the use of PPAR-α agonist, adrenergic receptor stimulation, thyroid hormone administration, irisin and FGF21 induction. Most of them act through the induction of PPAR-γ coactivator (PGC) 1-α and the consequent mitochondrial biogenesis and UCP1 induction. About the nutritional inducers, several compounds have been described with multiple mechanisms of action. Some of these activators include specific amino acids restriction, capsaicin, bile acids, Resveratrol, and retinoic acid. Besides that, some classes of lipids, as well as many plant extracts, have also been implicated in the browning of WAT. In conclusion, the discovery of browning in human WAT opens the possibility to target the adipose tissue to fight a range of diseases. Studies have arisen showing promising results and bringing new opportunities in thermogenesis and obesity control.

1 February 2015 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
TRTamiris Lima Rachid
Tamiris Lima Rachid
APAline Penna-De-Carvalho
Aline Penna-De-Carvalho
IBIsabele Bringhenti
Isabele Bringhenti
MAMarcia B. Aguila
Marcia B. Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
VSVanessa Souza-Mello
Vanessa Souza-Mello

8 September 2011 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
MCMariana Catta-Preta
Mariana Catta-Preta
LMLeonardo Souza Mendonca
Leonardo Souza Mendonca
JFJulio Fraulob-Aquino
Julio Fraulob-Aquino
MAMarcia Barbosa Aguila
Marcia Barbosa Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda

8 June 2010 in Clinical Science
Verified
Journal Article
Closed access
VSVanessa Souza-Mello
Vanessa Souza-Mello
BGBianca M. Gregório
Bianca M. Gregório
FCFernando S. Cardoso-De-Lemos
Fernando S. Cardoso-De-Lemos
LCLaís de Carvalho
Laís de Carvalho
MAMárcia B. Aguila
Márcia B. Aguila
CMCarlos Mandarim-De-Lacerda
Carlos Mandarim-De-Lacerda
The aim of the present study was to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, and pancreatic and hepatic remodelling in C57BL/6 mice fed on a very HF (high-fat) diet. Male C57BL/6 mice were fed on an HF (60% lipids) diet or SC (standard chow; 10% lipids) diet for 10 weeks, after which time the following drug treatments began: HF-T (HF diet treated with telmisartan; 5.2 mg·kg−1 of body weight·day−1), HF-S (HF diet treated with sitagliptin; 1.08 g·kg−1 of body weight·day−1), HF-M (HF diet treated with metformin; 310.0 mg·kg−1 of body weight·day−1), HF-TM (HF diet treated with telmisartan+metformin), HF-TS (HF diet treated with telmisartan+sitagliptin) and HF-SM (HF diet treated with sitagliptin+metformin). Treated groups also had free access to the HF diet, and treatments lasted for 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blot analysis and electron microscopy were used. The HF diet yielded an overweight phenotype, an increase in oral glucose intolerance, hyperinsulinaemia, hypertrophied islets and adipocytes, stage 2 steatosis (>33%), and reduced liver PPAR-α (peroxisome-proliferator-activated receptor-α) and GLUT-2 (glucose transporter-2) levels, concomitant with enhanced SREBP-1 (sterol-regulatory-element-binding protein-1) expression (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, a reversal of insulin resistance, islet and adipocyte hypertrophy, and alleviated hepatic steatosis. Only the HF-T and HF-TS groups had body weights similar to the SC group at the end of the experiment, and the latter treatment reversed hepatic steatosis. Increased PPAR-α immunostaining in parallel with higher GLUT-2 and reduced SREBP-1 expression may explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-α (tumour necrosis factor-α) levels (P<0.0001) in the drug-treated groups. In conclusion, all of the drug treatments were effective in controlling the metabolic syndrome. The best results were achieved using telmisartan and sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-γ agonism and PPAR-α activation in the liver with extended incretin action.